Revenue (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Total revenues $ 1,168 $ 2,270 $ 512 $ 391 $ 355 $ 571 $ 386 $ 514 $ 4,341 $ 1,826
Deferred revenue [1],[2] 50,500             50,500
Contract with Customer, Liability, Current 52,100               52,100  
Deferred Revenue, Current 18,119       193       18,119 193
[custom:DeferredRevenueUnfulfilledCommitments-0] 1,700               1,700  
[custom:ExpectedDeferredRevenueNoncurrent-0] 18,000               18,000  
Licensing Agreements [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Total revenues                 1,100  
Collaborative Arrangement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Total revenues                 100  
Deferred revenue         $ 100         $ 100
Unfulfilled Commitment [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Contract with Customer, Liability, Current 800               800  
Deferred Revenue, Current $ 49,700               $ 49,700  
[1] Excludes government grants as Lineage has determined government grants are outside the scope of ASU 2014-09 - Revenue from Contracts with Customers (Topic 606).
[2] Increase in accounts receivable due to accrual of $50.0 million upfront payment related to Roche Agreement, offset to deferred revenues.